Interestingly, ANXA4 translocation from plasma membrane to cytosol has been related to resistance to paclitaxel in lung cancer cells (Gaudio et al., 2016; Scala et al., 2021) and also its upregulation has been linked to cisplatin (CDDP) resistance in mesothelioma cells (Yamashita et al., 2012), ovarian clear cell carcinoma cells (Morimoto et al., 2014) and non-small cell lung cancer (NSCLC) cell lines (Zheng et al., 2018). Here, ANXA4 is linked to non-small cell lung carcinoma.